Oncolytics Biotech Inc. focuses on the discovery and development of pharmaceutical products for the treatment of a wide variety of human cancers. Headquartered in Calgary, Alberta, Canada, the Company was formed in 1998 to explore the oncolytic capability of the reovirus, a virus that preferentially replicates in cells with an activated Ras pathway, one of the most common family of genetic defects leading to cancer.
Reolysin, the company's proprietary formulation of the human reovirus, has been demonstrated to replicate specifically in tumour cells bearing an activated Ras pathway. Reolysin may represent a novel treatment for Ras activated tumour cells and some cellular proliferative disorders. from oncolyticsbiotech.com
I am an owner of Oncolytics Biotech Inc. stock (ONCY). This blog was created to serve as an archive of information, events, and news regarding this exciting company seeking novel treatments and cures for cancer.
No comments:
Post a Comment